Danazol was administered to two patients with paroxysmal nocturnal hemoglobinuria (PNH) with a dramatic effect on the hematological findings. The patients, 31-and 41-year-old females, were initially diagnosed as having aplastic anemia, and were initially treated with anabolic steroid and immunosuppressive therapy, respectively. Sugar water and Hamtests turned positive at the start of danazol therapy in the former patient and after two months in the latter patient. This drug produced a dramatic improvement in the hemoglobin level and the platelet count and showedfew side effects in the patients. A possible mechanismof action of danazol for PNHis briefly discussed.
virilizing effect, is administered for the treatment of endometriosis. Ahn et al (1) introduced this drug as an effective agent for the treatment of immune thrombocytopenic purpura (ITP), and it has also been reported to be useful in the treatment of autoimmune hemolytic anemia (AIHA) even when corticosteroids were ineffective (2). Furthermore, many reports have described the effects of this agent in patients with aplastic anemia (AA) (3), pure red cell aplasia (PRCA) (4) and myelodysplastic syndrome (MDS) (5, 6). Paroxysmal nocturnal hemoglobinuria (PNH) is a primary disorder of bone marrow hemopoietic cells characterized by an unusual susceptibility to the hemolytic action of complement (7, 8) . Pancytopenia and intravascular hemolysis followed by hemoglobinuria and subsequent renal damage in the course are sometimes difficult to control. tion. Severe pancytopenia was found and she was referred to our hospital immediately.
On admission, hematological findings revealed marked pancytopenia ( the platelet count was then maintained at approximately 50 X 109/l, as shown in Fig. 2 . All symptoms due to pancytopenia were alleviated, although facial acne and amenorrhea appeared after two months. Liver function was not affected by the agent.
DISCUSSION
Danazol is well knownto be effective in some patients with chronic ITP who have failed to respond to prednisolone (PSL), immunosuppressants and splenectomy (1 1 have a prior history of AA (21) . In patient 2, danazol was initially administered for the treatment of AA, and subsequently PNHdeveloped. It is not surprising that PNHshould arise from a defective clone in the marrowof AA.As the bone marrowbecame hyperplastic and the Hamtest turned positive with danazol treatment, it is probable that the agent accelerated the proliferation of an abnormal clone with increased susceptibility to complement. It is also probable, however, that not only overproduction of hemopoietic cells but also suppression of their complement-and macrophage-mediated lysis may have produced the subsequent increase of blood cells in the peripheral blood. Further studies to define the clinical effects of danazol on PHN clones, and particularly on the immune system, are therefore necessary.
